



Axicabtagene ciloleucel

REJECTED

The Expert Committee, after evaluation, declines to list the medicine proposed in the application.
The Model List of Essential Medicines reports reasons that Committee Members have identified for denying listing.

General description

ATC codes	L01XL03
Medicine type	Biological agent
EML status history	Application rejected in 2023 (TRS 1049) for Diffuse large B-cell lymphomas
Wikipedia	Axicabtagene ciloleucel 
DrugBank	Axicabtagene ciloleucel 

Recommendations

Section Antineoplastics and supportive medicines

Cell suspension for infusion: 2×10^6 anti-CD19 CAR-positive viable T-cells per kg of body weight.

Indications

Diffuse large B-cell lymphomas

